ETRAVIRINE (ETR, BRAND NAME INTELENCE, FORMERLY KNOWN AS TMC125) IS A DRUG USED FOR THE TREATMENT OF HIV. ETRAVIRINE IS A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI). UNLIKE THE CURRENTLY AVAILABLE AGENTS IN THE CLASS, RESISTANCE TO OTHERNNRTIS DOES NOT SEEM TO CONFER RESISTANCE TO ETRAVIRINE.

ETRAVIRINE (ETR, BRAND NAME INTRAVIR,I S A DRUG USED FOR THE TREATMENT OF HIV. ETRAVIRINE IS A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI). UNLIKE THE CURRENTLY AVAILABLE AGENTS IN THE CLASS, RESISTANCE TO OTHERNNRTIS DOES NOT SEEM TO CONFER RESISTANCE TO ETRAVIRINE.

INTRAVIR® (ETRAVIRINE), WHEN TAKEN WITH OTHER HIV MEDICINES, MAY HELP TO DECREASE VIRAL LOAD IN PATIENTS WHO ARE ALREADY TAKING OR HAVE TAKEN HIV MEDICINES, HAVE RESISTANCE TO NON-NUKES AND OTHER HIV MEDICINES, AND WHOSE HIV INFECTION IS NOT UNDER CONTROL.
INTRAVIR® IS NOT RIGHT FOR EVERYONE. ASK YOUR HEALTHCARE PROFESSIONAL IF INTRAVIR® IS RIGHT FOR YOU.
About INTRAVIR®

• INTRAVIR® (etravirine) is a prescription HIV (human immunodeficiency virus) medicine that is used with other HIV medicines to treat HIV infection in adults and children 6 years of age and older. HIV is the virus that causes AIDS (Acquired Immune Deficiency Syndrome). INTRAVIR® is a type of HIV medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI), also known as a non-nuke
• INTRAVIR® must be taken in combination with other HIV medicines. INTRAVIR® is used in people who are already taking or have taken an NNRTI and other HIV medicines and these medicines are not controlling their HIV infection
o The use of other medicines active against your HIV in combination with INTRAVIR®may increase the likelihood of your overall treatment response. If a non-nuke regimen has stopped working for you in the past, INTRAVIR® should not be taken with only nucleoside/nucleotide reverse transcriptase inhibitors, also known as nukes. Your healthcare professional will work with you to find the right combination of HIV medicines to combine with INTRAVIR®
o It is important that you remain under the care of your healthcare professional during treatment with INTRAVIR®
• It is not known if INTRAVIR® is safe and effective in children less than 6 years of age
INTRAVIR® does not cure HIV infection or AIDS. You must stay on continuous HIV therapy to control your HIV infection and decrease HIV-related illnesses.

Intravir is a drug used for the treatment of HIV. Intravir is a non-nucleoside reverse transcriptase inhibitor (NNRTIs). Unlike the currently available agents in the class, resistance to other NNRTIs does not seem to confer resistance to Intravir.

Indications and dosage

Intravir, in combination with other anti-retrovirals, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents.

The recommended dose of Intravir is 200 mg (two 100 mg tablets) taken twice daily following a meal. The type of food does not affect the exposure to Intravir.

General Information

Intravir is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1). Reverse transcriptase a viral DNA polymerase enzyme that HIV needs to reproduce. Intravir blocks the enzymatic function of reverse transcriptase and prevents completion of synthesis of the double-stranded viral DNA ,thus preventing HIV from multiplying.

Intravir, in combination with other antiretroviral agents, is specifically indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents.

Intravir is supplied as a tablet designed for oral administration. The recommended initial dose of the drug is 200 mg (two 100 mg tablets) taken twice daily following a meal. If a patient is unable to swallow a tablet whole, it may be dispersed in a glass of water.

Clinical Results
FDA Approval
FDA approval of Intravir was based on pooled 24-week results of two ongoing, identical phase III trials. These randomized, double-blinded, placebo-controlled studies were dubbed DUET-1 (TMC125-C206) and DUET-2 (TMC125-C216). The trials were designed to evaluate the safety and antiretroviral activity of Intravir in combination with a background regimen (BR) as compared to placebo in combination with a BR. Randomization was stratified by the intended use of enfuvirtide (ENF) in the BR, previous use of darunavir/ritonavir (DRV/rtv), and screening viral load. All study subjects received DRV/rtv as part of their BR, and at least two other investigator-selected antiretroviral drugs (N[t]RTIs with or without ENF. The endpoint was virologic response, defined as undetectable viral load (< 50 HIV-1 RNA copies/mL) at 24 weeks. At Week 24, 74% of Intellence-treated subjects achieved HIV-1 RNA < 400 copies/mL as compared to 51.5% of placebo-treated subjects. The mean decrease in plasma HIV-1 RNA from baseline to Week 24 was -2.37 log10 copies/mL for Intravir-treated subjects and -1.68 log10 copies/mL for placebo-treated subjects. The mean CD4+ cell count increase from baseline for Intravir-treated subjects was 81 cells/mm3 and 64 cells/mm3 for placebo-treated subjects. Of the population who either re-used or did not use ENF, 56.7% of Intravir-treated subjects and 32.7% of placebo-treated subjects achieved HIV-1 RNA < 50 copies/mL. Of the study population using ENF for the first time, 68.6% of Intravir-treated subjects and 61.3% of placebo-treated subjects achieved HIV-1 RNA < 50 copies/mL.




Side Effects
Adverse events associated with the use of Intravir may include, but are not limited to, the following:

* Rash
* Diarrhea
* Nausea
* Fatigue
* Abdominal pain
* Peripheral neuropathy
* Hypertension
* Headache

Mechanism of Action
Intravir is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1). Intravir binds directly to reverse transcriptase and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. Intravir does not inhibit the human DNA polymerases alpha, beta, and gamma.

Important Safety Information
Intravir does not cure HIV infection or AIDS, and does not prevent passing HIV to others.

* Severe skin rash has been reported with Intravir; Stevens-Johnson Syndrome has been rarely (<0.1 percent) reported. Treatment with Intravir should be discontinued if severe rash develops. In general, rash was mild to moderate, occurred primarily in the second week of therapy, and was infrequent after Week 4. Rash generally resolved within 1-2 weeks on continued therapy. Discontinuation rate due to rash was 2 percent.
* No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh Class A or B). The pharmacokinetics of Intravir have not been studied in patients with severe hepatic impairment (Child-Pugh Class C). Therefore, Intravir should be used with caution in patients with severe hepatic impairment.
* Based upon the safety profile, no dose adjustment is necessary in patients co-infected with hepatitis B and/or C virus.
* Redistribution and/or accumulation of body fat have been observed in patients receiving. ARV therapy. The causal relationship, mechanism, and long-term consequences of these events have not been established.
* Immune reconstitution syndrome has been reported in patients treated with ARV therapy, including Intravir.
* The most frequently reported adverse events (>10 percent) of any intensity that occurred at a higher rate than placebo were rash (17 percent), diarrhoea (15 percent) and nausea (13.9 percent).

Presentation
Intravir Tablets 100 mg             10, 20 Tablets / Botttle

Note : This product information is intended only for residents of the India. Taj Pharmaceuticals Limited,  medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited).
 

Drug used for the
Treatment of HIV
 

INTRAVIR® (ETRAVIRINE) DOSING INFORMATION
INTRAVIR® MUST BE TAKEN IN COMBINATION WITH OTHER HIV MEDICINES AS PRESCRIBED BY YOUR HEALTHCARE PROFESSIONAL
ADULT PATIENTS:
• THE DOSE IS 200 MG (ONE 200-MG TABLET) OF INTRAVIR® TWICE A DAY, EVERY DAY (A TOTAL OF 2 TABLETS EACH DAY)
o 100-MG TABLETS ARE STILL AVAILABLE. THE DOSE IS 200 MG (TWO 100-MG TABLETS) OF INTRAVIR® TWICE A DAY, EVERY DAY (A TOTAL OF 4 TABLETS EACH DAY)
• TAKE INTRAVIR® TWICE A DAY FOLLOWING A MEAL. THE TYPE OF FOOD IS NOT IMPORTANT. DO NOT TAKE INTRAVIR® ON AN EMPTY STOMACH, AS IT MAY NOT WORK AS WELL AS IT SHOULD
• SWALLOW THE TABLETS WHOLE WITH WATER. DO NOT CHEW THE TABLETS

Select Language English Russian French German Italian Japanese Korean Portuguese Spanish Greek Dutch Hindi

              
 Print page   Send by mail